Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 320

1.

On high-risk, low-grade glioma: What distinguishes high from low?

Geurts M, van den Bent MJ.

Cancer. 2018 Dec 4. doi: 10.1002/cncr.31834. [Epub ahead of print] No abstract available.

PMID:
30512190
2.

Clinical evaluation of a dedicated next generation sequencing panel for routine glioma diagnostics.

Synhaeve NE, van den Bent MJ, French PJ, Dinjens WNM, Atmodimedjo PN, Kros JM, Verdijk R, Dirven CMF, Dubbink HJ.

Acta Neuropathol Commun. 2018 Nov 23;6(1):126. doi: 10.1186/s40478-018-0633-y.

3.

Novel methods to diagnose leptomeningeal metastases in breast cancer.

Angus L, Martens JWM, van den Bent MJ, Sillevis Smitt PAE, Sleijfer S, Jager A.

Neuro Oncol. 2018 Nov 10. doi: 10.1093/neuonc/noy186. [Epub ahead of print]

PMID:
30418595
4.

Precision Medicine for Primary Central Nervous System Tumors: Are We There Yet?

Ippen FM, Colman H, van den Bent MJ, Brastianos PK.

Am Soc Clin Oncol Educ Book. 2018 May 23;(38):158-167. doi: 10.1200/EDBK_199247. Review.

5.

First results on the DCVax phase III trial: raising more questions than providing answers.

Wick W, van den Bent MJ.

Neuro Oncol. 2018 Sep 3;20(10):1283-1284. doi: 10.1093/neuonc/noy125. No abstract available.

PMID:
30137551
6.

Bevacizumab and temozolomide in patients with first recurrence of WHO grade II and III glioma, without 1p/19q co-deletion (TAVAREC): a randomised controlled phase 2 EORTC trial.

van den Bent MJ, Klein M, Smits M, Reijneveld JC, French PJ, Clement P, de Vos FYF, Wick A, Mulholland PJ, Taphoorn MJB, Lewis J, Weller M, Chinot OL, Kros JM, de Heer I, Verschuere T, Coens C, Golfinopoulos V, Gorlia T, Idbaih A.

Lancet Oncol. 2018 Sep;19(9):1170-1179. doi: 10.1016/S1470-2045(18)30362-0. Epub 2018 Aug 13.

PMID:
30115593
7.

Cognitive functioning and health-related quality of life in patients with newly diagnosed primary CNS lymphoma: a systematic review.

van der Meulen M, Dirven L, Habets EJJ, van den Bent MJ, Taphoorn MJB, Bromberg JEC.

Lancet Oncol. 2018 Aug;19(8):e407-e418. doi: 10.1016/S1470-2045(18)30356-5. Review.

PMID:
30102235
8.

Grade II and III Oligodendroglioma and Astrocytoma.

van den Bent MJ, Chang SM.

Neurol Clin. 2018 Aug;36(3):467-484. doi: 10.1016/j.ncl.2018.04.005. Epub 2018 Jun 15. Review.

PMID:
30072066
9.

Safety and efficacy of depatuxizumab mafodotin + temozolomide in patients with EGFR-amplified, recurrent glioblastoma: results from an international phase I multicenter trial.

Lassman AB, van den Bent MJ, Gan HK, Reardon DA, Kumthekar P, Butowski N, Lwin Z, Mikkelsen T, Nabors LB, Papadopoulos KP, Penas-Prado M, Simes J, Wheeler H, Walbert T, Scott AM, Gomez E, Lee HJ, Roberts-Rapp L, Xiong H, Ansell PJ, Bain E, Holen KD, Maag D, Merrell R.

Neuro Oncol. 2018 Jul 5. doi: 10.1093/neuonc/noy091. [Epub ahead of print]

PMID:
29982805
10.

Corticosteroid use endpoints in neuro-oncology: Response Assessment in Neuro-Oncology Working Group.

Arvold ND, Armstrong TS, Warren KE, Chang SM, DeAngelis LM, Blakeley J, Chamberlain MC, Dunbar E, Loong HH, Macdonald DR, Reardon DA, Vogelbaum MA, Yuan Y, Weller M, van den Bent M, Wen PY.

Neuro Oncol. 2018 Jun 18;20(7):897-906. doi: 10.1093/neuonc/noy056.

PMID:
29788429
11.

Timing of radiotherapy in newly diagnosed glioblastoma: no need to rush?

Geurts M, van den Bent MJ.

Neuro Oncol. 2018 Jun 18;20(7):868-869. doi: 10.1093/neuonc/noy065. No abstract available.

PMID:
29767783
12.

Flow cytometry shows added value in diagnosing lymphoma in brain biopsies.

van der Meulen M, Bromberg JEC, Lam KH, Dammers R, Langerak AW, Doorduijn JK, Kros JM, van den Bent MJ, van der Velden VHJ.

Cytometry B Clin Cytom. 2018 Nov;94(6):928-934. doi: 10.1002/cyto.b.21641. Epub 2018 Sep 3.

PMID:
29747221
13.

Pseudoprogression of brain tumors.

Thust SC, van den Bent MJ, Smits M.

J Magn Reson Imaging. 2018 May 7. doi: 10.1002/jmri.26171. [Epub ahead of print]

14.

Novel, improved grading system(s) for IDH-mutant astrocytic gliomas.

Shirahata M, Ono T, Stichel D, Schrimpf D, Reuss DE, Sahm F, Koelsche C, Wefers A, Reinhardt A, Huang K, Sievers P, Shimizu H, Nanjo H, Kobayashi Y, Miyake Y, Suzuki T, Adachi JI, Mishima K, Sasaki A, Nishikawa R, Bewerunge-Hudler M, Ryzhova M, Absalyamova O, Golanov A, Sinn P, Platten M, Jungk C, Winkler F, Wick A, Hänggi D, Unterberg A, Pfister SM, Jones DTW, van den Bent M, Hegi M, French P, Baumert BG, Stupp R, Gorlia T, Weller M, Capper D, Korshunov A, Herold-Mende C, Wick W, Louis DN, von Deimling A.

Acta Neuropathol. 2018 Jul;136(1):153-166. doi: 10.1007/s00401-018-1849-4. Epub 2018 Apr 23.

PMID:
29687258
15.

Prognostic relevance of mutations and copy number alterations assessed with targeted next generation sequencing in IDH mutant grade II glioma.

Wijnenga MMJ, French PJ, Dubbink HJ, Dinjens WNM, Atmodimedjo PN, Kros JM, Fleischeuer R, Dirven CMF, Vincent AJPE, van den Bent MJ.

J Neurooncol. 2018 Sep;139(2):349-357. doi: 10.1007/s11060-018-2867-8. Epub 2018 Apr 16.

16.

Efficacy of intrathecal chemotherapy in patients with central nervous system involvement of hematological malignancies: a retrospective analysis.

Dara A, Mook BB, Doorduijn JK, van den Bent MJ, Dinmohamed AG, Bromberg JEC.

J Neurooncol. 2018 Aug;139(1):117-123. doi: 10.1007/s11060-018-2849-x. Epub 2018 Apr 9.

PMID:
29633110
17.

Radiotherapy quality assurance for the RTOG 0834/EORTC 26053-22054/NCIC CTG CEC.1/CATNON intergroup trial "concurrent and adjuvant temozolomide chemotherapy in newly diagnosed non-1p/19q deleted anaplastic glioma": Individual case review analysis.

Abrunhosa-Branquinho AN, Bar-Deroma R, Collette S, Clementel E, Liu Y, Hurkmans CW, Feuvret L, Van Beek K, van den Bent M, Baumert BG, Weber DC.

Radiother Oncol. 2018 May;127(2):292-298. doi: 10.1016/j.radonc.2018.03.013. Epub 2018 Mar 29.

PMID:
29606522
18.

The T2-FLAIR mismatch sign as an imaging marker for non-enhancing IDH-mutant, 1p/19q-intact lower-grade glioma: a validation study.

Broen MPG, Smits M, Wijnenga MMJ, Dubbink HJ, Anten MHME, Schijns OEMG, Beckervordersandforth J, Postma AA, van den Bent MJ.

Neuro Oncol. 2018 Sep 3;20(10):1393-1399. doi: 10.1093/neuonc/noy048.

PMID:
29590424
19.

Expression-based intrinsic glioma subtypes are prognostic in low-grade gliomas of the EORTC22033-26033 clinical trial.

Gao Y, Weenink B, van den Bent MJ, Erdem-Eraslan L, Kros JM, Sillevis Smitt P, Hoang-Xuan K, Brandes AA, Vos M, Dhermain F, Enting R, Ryan GF, Chinot O, Ben Hassel M, van Linde ME, Mason WP, Gijtenbeek JMM, Balana C, von Deimling A, Gorlia T, Stupp R, Hegi ME, Baumert BG, French PJ.

Eur J Cancer. 2018 May;94:168-178. doi: 10.1016/j.ejca.2018.02.023. Epub 2018 Mar 20.

PMID:
29571083
20.

cIMPACT-NOW update 2: diagnostic clarifications for diffuse midline glioma, H3 K27M-mutant and diffuse astrocytoma/anaplastic astrocytoma, IDH-mutant.

Louis DN, Giannini C, Capper D, Paulus W, Figarella-Branger D, Lopes MB, Batchelor TT, Cairncross JG, van den Bent M, Wick W, Wesseling P.

Acta Neuropathol. 2018 Apr;135(4):639-642. doi: 10.1007/s00401-018-1826-y. Epub 2018 Mar 1. No abstract available.

PMID:
29497819

Supplemental Content

Loading ...
Support Center